Literature DB >> 16395606

Clozapine binds preferentially to cortical D1-like dopamine receptors in the primate brain: a PET study.

Yuan-Hwa Chou1, Christer Halldin, Lars Farde.   

Abstract

RATIONALE: The D1-like dopamine receptors have been suggested to play a role in the pathophysiology and treatment of schizophrenia. Previous positron emission tomography studies have demonstrated that the atypical antipsychotic clozapine occupies D1-like dopamine receptors in the striatum in clozapine-treated patients.
OBJECTIVES: The aim of the present study was to compare striatal and cortical D1-like dopamine receptor occupancy by clozapine in the primate brain.
METHODS: Three monkeys were each examined three times at the same day with the radioligand (+)-[11C]NNC 112. The first measurement was at baseline conditions, the second after 1.5 mg/kg and the third after 6 mg/kg clozapine IV. To compare regional levels of nonspecific binding in brain regions, an additional monkey was examined using the inactive enantiomer (-)-[11C]NNC 112. Receptor occupancy was calculated using both the equilibrium-ratio analysis and the simplified reference tissue model.
RESULTS: After 1.5 mg/kg the D1-like dopamine receptor occupancy ranged from 30 to 38% in the striatum, whereas the range was 51 to 57% in the frontal cortex. After 6.0 mg/kg the occupancy was 53 to 64% in the striatum and 63 to 83% in the frontal cortex. The differences between striatal and cortical D(1)-like receptors occupancy were between 12 and 25%. The study with (-)-[11C]NNC 112 did not show regional differences in nonspecific binding that might explain the regional differences in occupancy.
CONCLUSIONS: The higher D1-like dopamine receptor occupancy in the frontal cortex may reflect a different distribution of the D1 and D5 dopamine receptor subtypes among brain regions and different affinity of clozapine for the two subtypes. The finding supports the suggestion that binding to D1-like dopamine receptors may explain clozapine's atypical drug actions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16395606     DOI: 10.1007/s00213-005-0219-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  33 in total

Review 1.  Clozapine. A novel antipsychotic agent.

Authors:  R J Baldessarini; F R Frankenburg
Journal:  N Engl J Med       Date:  1991-03-14       Impact factor: 91.245

2.  Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.

Authors:  R K Sunahara; H C Guan; B F O'Dowd; P Seeman; L G Laurier; G Ng; S R George; J Torchia; H H Van Tol; H B Niznik
Journal:  Nature       Date:  1991-04-18       Impact factor: 49.962

3.  D1 dopamine receptors in prefrontal cortex: involvement in working memory.

Authors:  T Sawaguchi; P S Goldman-Rakic
Journal:  Science       Date:  1991-02-22       Impact factor: 47.728

4.  D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics.

Authors:  L Farde; F A Wiesel; A L Nordström; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  Modulation of memory fields by dopamine D1 receptors in prefrontal cortex.

Authors:  G V Williams; P S Goldman-Rakic
Journal:  Nature       Date:  1995-08-17       Impact factor: 49.962

6.  A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex.

Authors:  M S Lidow; P S Goldman-Rakic
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

7.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

8.  Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.

Authors:  Y Okubo; T Suhara; K Suzuki; K Kobayashi; O Inoue; O Terasaki; Y Someya; T Sassa; Y Sudo; E Matsushima; M Iyo; Y Tateno; M Toru
Journal:  Nature       Date:  1997-02-13       Impact factor: 49.962

9.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.

Authors:  L Farde; A L Nordström; F A Wiesel; S Pauli; C Halldin; G Sedvall
Journal:  Arch Gen Psychiatry       Date:  1992-07

10.  D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients.

Authors:  A L Nordström; L Farde; S Nyberg; P Karlsson; C Halldin; G Sedvall
Journal:  Am J Psychiatry       Date:  1995-10       Impact factor: 18.112

View more
  7 in total

1.  Desorption electrospray ionization mass spectrometry: Imaging drugs and metabolites in tissues.

Authors:  Justin M Wiseman; Demian R Ifa; Yongxin Zhu; Candice B Kissinger; Nicholas E Manicke; Peter T Kissinger; R Graham Cooks
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-12       Impact factor: 11.205

2.  PET imaging of the brain serotonin transporters (SERT) with N,N-dimethyl-2-(2-amino-4-[18F]fluorophenylthio)benzylamine (4-[18F]-ADAM) in humans: a preliminary study.

Authors:  Wen-Sheng Huang; San-Yuan Huang; Pei-Shen Ho; Kuo-Hsing Ma; Ya-Yao Huang; Chin-Bin Yeh; Ren-Syuan Liu; Cheng-Yi Cheng; Chyng-Yann Shiue
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-05       Impact factor: 9.236

3.  AMPA receptor subunit and splice variant expression in the DLPFC of schizophrenic subjects and rhesus monkeys chronically administered antipsychotic drugs.

Authors:  J A O'Connor; E C Muly; S E Arnold; S E Hemby
Journal:  Schizophr Res       Date:  2006-12-01       Impact factor: 4.939

Review 4.  α2-Adrenoceptors are targets for antipsychotic drugs.

Authors:  Jan Brosda; Florian Jantschak; Heinz H Pertz
Journal:  Psychopharmacology (Berl)       Date:  2014-02-02       Impact factor: 4.530

Review 5.  Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology.

Authors:  Rodrigo D Paz; Sonia Tardito; Marco Atzori; Kuei Y Tseng
Journal:  Eur Neuropsychopharmacol       Date:  2008-07-23       Impact factor: 4.600

6.  In vivo DA D(1) receptor selectivity of NNC 112 and SCH 23390.

Authors:  Jesper Ekelund; Mark Slifstein; Raj Narendran; Olivier Guillin; Hemant Belani; Ning-Ning Guo; Yuying Hwang; Dah-Ren Hwang; Anissa Abi-Dargham; Marc Laruelle
Journal:  Mol Imaging Biol       Date:  2007 May-Jun       Impact factor: 3.484

7.  Does changing from a first generation antipsychotic (perphenazin) to a second generation antipsychotic (risperidone) alter brain activation and motor activity? A case report.

Authors:  Jan Øystein Berle; Else-Marie Løberg; Ole Bernt Fasmer
Journal:  BMC Res Notes       Date:  2013-05-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.